EP1545493A4 - Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit neovaskularisierung - Google Patents

Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit neovaskularisierung

Info

Publication number
EP1545493A4
EP1545493A4 EP03767196A EP03767196A EP1545493A4 EP 1545493 A4 EP1545493 A4 EP 1545493A4 EP 03767196 A EP03767196 A EP 03767196A EP 03767196 A EP03767196 A EP 03767196A EP 1545493 A4 EP1545493 A4 EP 1545493A4
Authority
EP
European Patent Office
Prior art keywords
neovascularization
compositions
methods
conditions associated
treat conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03767196A
Other languages
English (en)
French (fr)
Other versions
EP1545493A2 (de
Inventor
Kin-Ping Wong
Ming-Chung Wong
Dai Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wackvom Ltd
Original Assignee
Wackvom Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wackvom Ltd filed Critical Wackvom Ltd
Publication of EP1545493A2 publication Critical patent/EP1545493A2/de
Publication of EP1545493A4 publication Critical patent/EP1545493A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03767196A 2002-08-05 2003-08-05 Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit neovaskularisierung Withdrawn EP1545493A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40113002P 2002-08-05 2002-08-05
US401130P 2002-08-05
PCT/US2003/024455 WO2004012677A2 (en) 2002-08-05 2003-08-05 Methods and compositions to treat conditions associated with neovascularization

Publications (2)

Publication Number Publication Date
EP1545493A2 EP1545493A2 (de) 2005-06-29
EP1545493A4 true EP1545493A4 (de) 2006-01-11

Family

ID=31495928

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03767196A Withdrawn EP1545493A4 (de) 2002-08-05 2003-08-05 Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit neovaskularisierung

Country Status (6)

Country Link
EP (1) EP1545493A4 (de)
JP (1) JP2006508047A (de)
CN (1) CN1723017A (de)
AU (1) AU2003263988A1 (de)
TW (1) TW200407119A (de)
WO (1) WO2004012677A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1897972A (zh) * 2003-12-22 2007-01-17 爱尔康公司 用于治疗青光眼性视网膜病和视神经病的活性剂
CA2606382C (en) * 2005-04-29 2014-10-07 Johns Hopkins University Methods of supressing uv light-induced skin carcinogenesis
US20100015085A1 (en) * 2006-05-01 2010-01-21 Johns Hopkins University Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress
JP2011500680A (ja) * 2007-10-16 2011-01-06 ジョンズ・ホプキンス・ユニヴァーシティ 放射線傷害から皮膚を保護する方法
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
US9532970B2 (en) 2014-07-09 2017-01-03 Darlene E. McCord Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045829A1 (en) * 1999-02-02 2000-08-10 Wassen International Limited Brassica extracts or sulforaphane in combination with resveratrol as antitumor agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
US6433011B1 (en) 2000-03-08 2002-08-13 American Health Foundation Method for inhibiting formation of aberrant crypt foci in the colon of a mammal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045829A1 (en) * 1999-02-02 2000-08-10 Wassen International Limited Brassica extracts or sulforaphane in combination with resveratrol as antitumor agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHIAO J W ET AL: "Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 20, no. 3, March 2002 (2002-03-01), pages 631 - 636, XP009056886, ISSN: 1019-6439 *
FIMOGNARI CARMELA ET AL: "Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane", CARCINOGENESIS (OXFORD), vol. 23, no. 4, April 2002 (2002-04-01), pages 581 - 586, XP002353392, ISSN: 0143-3334 *
GAMET-PAYRASTRE LAURENCE ET AL: "Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells", CANCER RESEARCH, vol. 60, no. 5, 1 March 2000 (2000-03-01), pages 1426 - 1433, XP002353391, ISSN: 0008-5472 *
LUND ELIZABETH K ET AL: "Cell death in the colorectal cancer cell line HT29 in response to glucosinolate metabolites", JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, vol. 81, no. 9, July 2001 (2001-07-01), pages 959 - 961, XP002353393, ISSN: 0022-5142 *
MATUSHESKI NATHAN V ET AL: "Comparison of the bioactivity of two glucoraphanin hydrolysis products found in broccoli, sulforaphane and sulforaphane nitrile", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 49, no. 12, December 2001 (2001-12-01), pages 5743 - 5749, XP002353573, ISSN: 0021-8561 *
See also references of WO2004012677A2 *
ZHANG YUESHENG; KENSLER THOMAS W; CHO CHEON-GYU; POSNER GARY H; TALALAY PAUL: "Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates", PROC. NATL. ACAD. SCI, vol. 91, no. 8, 1994, pages 3147 - 3150 *

Also Published As

Publication number Publication date
TW200407119A (en) 2004-05-16
WO2004012677A3 (en) 2005-02-24
AU2003263988A8 (en) 2004-02-23
CN1723017A (zh) 2006-01-18
EP1545493A2 (de) 2005-06-29
AU2003263988A1 (en) 2004-02-23
JP2006508047A (ja) 2006-03-09
WO2004012677A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
GB2423928B (en) Methods and compositions for treating pain
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
EP1737482A4 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten
IL188420A0 (en) Methods and compositions with enhanced therapeutic activity
IL191072A0 (en) Therapeutic compositions and methods
EP1827362A4 (de) Zusammensetzungen und anwendungsverfahren zur verbesserung des zustands und des aussehens der haut
IL229039A0 (en) Solid preparations and methods for treating insomnia in the middle of the night
EP1703907A4 (de) Zusammensetzungen und verfahren zur behandlung von rezidivierenden krankheiten
AU2002230888A1 (en) Methods and compositions to treat conditions associated with neovascularization
GB0303609D0 (en) Novel therapeutic method and compositions
ZA200508655B (en) Compositions and methods relating to stop-1
GB0219568D0 (en) Improvements in and to compositions
EP1786265A4 (de) Neue zusammensetzungen und behandlungsverfahren
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1670314A4 (de) Verfahren und zusammensetzungen enthaltend diamine als neue therapeutika für tuberkulose
AU2003263988A8 (en) Methods and compositions to treat conditions associated with neovascularization
GB0324523D0 (en) Compositions and methods of treatment
EP1601348A4 (de) Zusammensetzungen und verfahren mit verbesserter therapeutischer aktivität
IL180195A0 (en) Aequorin-containing compositions and methods of using same
GB0418762D0 (en) Methods and compositions to treat glaucoma
GB0327050D0 (en) Therapeutic methods compositions and uses
AU2003257965A8 (en) Phosphonamide and phosphonamide blend compositions and method to treat water
GB0303600D0 (en) Novel therapeutic method and compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050303

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20051124

17Q First examination report despatched

Effective date: 20060724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302